US FDA Deems Synapse’s Clinical Trials ‘Unacceptable’

 
• By Urtė Fultinavičiūtė
One line illustration of hangs gestures indicating dispute or disapproval
The FDA downgraded several products to a BX rating after raising data integrity concerns at a CRO. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics